Abstract
Patients with severe mental illnesses, such as schizophrenia and bipolar disorder, are at increased risk of developing metabolic disorders including obesity, diabetes, and dyslipidemia. All of these comorbidities increase the risk of cardiovascular disease and mortality. Different approaches, including diet and lifestyle modifications, behavioral therapy and switching antipsychotic agents, have been proposed to manage these metabolic abnormalities. However, these interventions may be insufficient, impractical or fail to counteract the metabolic dysregulation. Consequently, a variety of pharmacological agents such as antidiabetic drugs, have been studied in an attempt to reverse the weight gain and metabolic abnormalities evident in these patients. Despite a significant effect, many of these treatments are used off-label. This qualitative review focuses on pharmacological agents that could offer significant benefits in the management of cardio-metabolic disorders associated with serious mental illness.
Keywords: Antipsychotic-induced weight gain, bipolar disorder, cardiovascular risk, metformin, metabolic syndrome, off-label use, schizophrenia, severe mental illness.
Current Pharmaceutical Design
Title:Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness
Volume: 21 Issue: 23
Author(s): Youssef Kouidrat, Ali Amad and Marc De Hert
Affiliation:
Keywords: Antipsychotic-induced weight gain, bipolar disorder, cardiovascular risk, metformin, metabolic syndrome, off-label use, schizophrenia, severe mental illness.
Abstract: Patients with severe mental illnesses, such as schizophrenia and bipolar disorder, are at increased risk of developing metabolic disorders including obesity, diabetes, and dyslipidemia. All of these comorbidities increase the risk of cardiovascular disease and mortality. Different approaches, including diet and lifestyle modifications, behavioral therapy and switching antipsychotic agents, have been proposed to manage these metabolic abnormalities. However, these interventions may be insufficient, impractical or fail to counteract the metabolic dysregulation. Consequently, a variety of pharmacological agents such as antidiabetic drugs, have been studied in an attempt to reverse the weight gain and metabolic abnormalities evident in these patients. Despite a significant effect, many of these treatments are used off-label. This qualitative review focuses on pharmacological agents that could offer significant benefits in the management of cardio-metabolic disorders associated with serious mental illness.
Export Options
About this article
Cite this article as:
Kouidrat Youssef, Amad Ali and De Hert Marc, Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness, Current Pharmaceutical Design 2015; 21 (23) . https://dx.doi.org/10.2174/1381612821666150619093128
DOI https://dx.doi.org/10.2174/1381612821666150619093128 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Increasing High-Density Lipoprotein Cholesterol Through Cholesteryl Ester Transfer Protein Inhibition: A Next Step in the Fight Against Cardiovascular Disease?
Current Drug Targets - Cardiovascular & Hematological Disorders Novel Quercetin Glycosides as Potent Anti-MRSA and Anti-VRE Agents
Recent Patents on Anti-Infective Drug Discovery Ventricular and Vascular Stiffening in Aging and Hypertension
Current Hypertension Reviews Correlates of Physical Activity of Children and Adolescents with Visual Impairments: A Systematic Review
Current Pharmaceutical Design Lipids, Statins and Heart Failure: An Update
Current Pharmaceutical Design Cardiovascular Risk in Perimenopausal Women
Current Vascular Pharmacology Endoplasmic Stress Inhibitors for Homocysteine Induced Cardiovascular Disease
Current Pharmaceutical Design Infection, its Treatment and the Risk for Stroke
Current Vascular Pharmacology Atrial Fibrillation Following Cardiac Surgery: Established and Emerging Strategies of Prevention
Recent Patents on Cardiovascular Drug Discovery Pharmacologic Therapy for Cardiovascular Risk Reduction in Patients with the Metabolic Syndrome
Current Pharmaceutical Design Statins for the Prevention of First or Recurrent Stroke
Current Vascular Pharmacology Editorial [ Hot Topic: Current Topics on the Epidemiology, Pathogenesis, and Treatment of Diabetes Mellitus and its Complications (Guest Editors: Moses S. Elisaf and Evangelos C. Rizos)]
Current Vascular Pharmacology Sedation in PACU: The Role of Propofol
Current Drug Targets Cardiac Stem Cell-Based Myocardial Regeneration: Towards a Translational Approach
Cardiovascular & Hematological Agents in Medicinal Chemistry G Protein-Coupled Receptors in Regulation of Body Weight
CNS & Neurological Disorders - Drug Targets In-vitro Studies on α-Amylase, α-Glucosidase and Aldose Reductase Inhibitors found in Endophytic Fungi Isolated from Ocimum sanctum
Current Enzyme Inhibition Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk
Current Pharmaceutical Design Coronary Atherosclerotic Disease Burden: An Emerging Endpoint in Progression / Regression Studies Using Intravascular Ultrasound
Current Drug Targets - Cardiovascular & Hematological Disorders Synthesis and Evaluation of 1-hydroxybenzotriazole Derivatives: Dual Inhibitors of Carbonic Anhydrase II and Sodium Hydrogen Exchanger I
Letters in Organic Chemistry Calcific Aortic Stenosis: Molecular and Cellular Mechanisms, Medical Treatment Alternatives
Current Cardiology Reviews